Venise ANN Atoigue

Venise ANN Atoigue is a woman-owned small business and self-certified small disadvantaged business registered as a sole proprietorship located in Bristow, Virginia. The company specializes in providing medical expert services and case review support to federal government agencies, with a primary focus on healthcare-related consulting and evaluation services. As a minority-owned and woman-owned business, Atoigue has positioned itself to serve federal agencies through specialized medical review and expert analysis contracts.

The company has been awarded multiple federal contract call orders primarily with the Department of Health and Human Services' Health Resources and Services Administration (HRSA), specifically supporting the Vaccine Injury Compensation Program (VICP) and Countermeasures Injury Compensation Program (CICP). These contracts involve detailed medical case reviews, where Atoigue provides expert medical evaluation and analysis for specific vaccine injury claims. The contract awards have varied in value from $6,250 to $25,000 per call order, with some designated as total small business set-asides and others without specific set-aside designations. The work is consistently performed in Bristow, Virginia, and involves reviewing and analyzing complex medical cases related to vaccine injuries and potential compensation claims.

Venise ANN Atoigue holds a single-award Blanket Purchase Agreement (BPA) with HRSA, identified by the contract number 75R60223A00008, which has a total ceiling value of $7,500,000 and an ultimate completion date of April 2, 2028. This BPA serves as the umbrella vehicle under which multiple call orders have been issued for medical case review services. The BPA specifically supports the VICP and CICP programs, enabling Atoigue to provide critical medical expert services that help determine eligibility and adjudicate petitions for compensation related to covered childhood vaccines and medical countermeasures. The contract is classified as a civilian agency agreement and allows for firm fixed-price call orders that support the important public health function of evaluating potential vaccine-related injury claims.